Tazemetostat not checked
Epizyme, Inc. · EPZ-6438 · E7438
FollowEvery change as it happens, and a Monday email
Trials
2 active
17 in total · 5 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Stage 1 (Phase 1b): Tazemetostat was escalated from a starting dose of 400 mg orally twice daily to 600 mg orally twice daily to 800 mg PO twice daily in 28-day cycles as tolerated in a standard 3 + 3 design. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy. Following implementation of the urgent…”In the company’s words, NCT04224493 on ClinicalTrials.gov
- Tested for
- Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
- Main trialPhase 3
- “The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial studied the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2…”In the company’s words, NCT04224493 on ClinicalTrials.gov
- Other names
- EPZ-6438 · E7438 · IPN60200 · Tazverik
Other drugs for Relapsed/Refractory Follicular Lymphoma
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- EpcoritamabGenmab · Phase 3
- OdronextamabRegeneron · Phase 3
- SurovatamigAstraZeneca · Phase 3
- GolcadomideCelgene · Phase 3
- SCTB35Sinocelltech · Phase 3
Coming up1
- 13 Feb 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials17
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 13 Feb 2027 | A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | |
| Phase 2Completed | Jun 2018 | Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma | |
| Phase 2Terminated | 22 Mar 2022 | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma | |
| Phase 2Completed | 26 Feb 2024 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | |
| Phase 2Withdrawn | 6 Apr 2029 | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation | |
| Phase 1/2Completed | 24 Aug 2021 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | |
| Phase 1/2Withdrawn | 5 Jul 2023 | A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. | |
| Phase 1/2Terminated | 4 Nov 2024 | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer | |
| Phase 1/2Terminated | 26 Sep 2025 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study | |
| Phase 1Completed | 8 Jan 2019 | Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors | |
| Phase 1Completed | 31 Oct 2019 | Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients | |
| Phase 1Completed | 19 Jun 2021 | EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | |
| Phase 1Completed | 3 Apr 2023 | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels | |
| Phase 1Terminated | 14 Jun 2024 | Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | |
| Phase 1Terminated | 12 Mar 2025 | A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function | |
| Phase 2Ended | not given | CAIRE : COMBINING EPIGENETIC AND IMMUNE THERAPY TO BEAT CANCER | |
| Phase 1/2Authorised | not given | Epi-RCHOP A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL) patients treated by R-CHOP |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026